Botanical species · safety record

Farfugium japonicum

The EFSA Compendium of Botanicals holds 8 constituent measurements and 1 adverse-effect record for Farfugium japonicum. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Farfugium japonicum (L.) Kitam

8Constituent measurements

1Safety records

8Cited sources

0Licensed products (Canada)

Regulatory presence

No Health Canada licensed natural health product in the snapshot names this species as a medicinal ingredient under this exact binomial. Absence here means absence from this one register under this one name, not absence from trade, and not a safety verdict.

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Farfugine	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Farfugine	Unspecified	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Furan derivatives	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Petasitenine	Live plants	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Senkirkine	Unspecified	—	—	Unspecified	Resolve DOI
Sesquiterpene lactones	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Sesquiterpene lactones	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Furan derivatives	Roots and other underground parts	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Hepatotoxicity	Liver	Aerial part of plants	—	Rat (as animal)	Chronic/long term toxicity	Resolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

HIRONO, I., UENO, I., AISO, S., YAMAJI, T., HAGA, M. CARCINOGENIC ACTIVITY OF FARFUGIUM-JAPONICUM AND SENECIO-CANNABIFOLIUS. CANCER LETTERS, 1983, vol. 20, no. 2, p. 191-198. DOI
NIWA, H., ISHIWATA, H., YAMADA, K. ISOLATION OF PETASITENINE, A CARCINOGENIC PYRROLIZIDINE ALKALOID FROM FARFUGIUM-JAPONICUM. JOURNAL OF NATURAL PRODUCTS, 1985, vol. 48, no. 6, p. 1003-1004. DOI
NAGANO, H., MORIYAMA, Y., SATO, K., TAKAHASH.T., TANAHASH.Y., FUKUYAMA, M. FARFUGIN A AND B, NEW SESQUITERPENES FROM FARFUGIUM-JAPONICUM. Chemistry letters, 1972, no. 1, p. 13-+. DOI
Nagano, Hajime., Tanahashi, Yoshiaki., Moriyama, Yoshihiko., Takahashi, Takeyoshi. New furanoeremophilane derivatives from Farfugium japonicum. Bulletin of the chemical society of japan, 1973, p. 2840-2845.
Tori, M., Shiotani, Y., Tanaka, M., Nakashima, K., Sono, M. Eremofarfugin A and eremopetasitenin B-3, two new eremophilanolides from Farfugium japonicum. TETRAHEDRON LETTERS, 2000, vol. 41, no. 11, p. 1797-1799. DOI
Tori, Motoo., Otose, Kanako., Fukuyama, Hiroko., Murata, Junko., Shiotani, Yasuko., Takaoka, Shigeru., Nakashima, Katsuyuki., Sono, Masakazu., Tanaka, Masami. New eremophilanes from Farfugium japonicum. Tetrahedron, 2010, vol. 66, no. 27-28, p. 5235-5243. DOI
NIWA, H., ISHIWATA, H., KURODA, A., YAMADA, K. FARFUGINE, A NEW PYRROLIZIDINE ALKALOID ISOLATED FROM FARFUGIUM-JAPONICUM KITAM. CHEMISTRY LETTERS, 1983, no. 5, p. 789-790. DOI
Zhou, Jue., Ouedraogo, Moustapha., Qu, Fan., Duez, Pierre. Potential Genotoxicity of Traditional Chinese Medicinal Plants and Phytochemicals: An Overview. PHYTOTHERAPY RESEARCH, 2013, vol. 27, no. 12, p. 1745-1755. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature